Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Income towards Parent Company (2016 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Income towards Parent Company over the past 15 years, most recently at $3000.0 for Q2 2024.

  • For Q2 2024, Income towards Parent Company rose 100.13% year-over-year to $3000.0; the TTM value through Feb 2025 reached $3000.0, down 99.22%, while the annual FY2024 figure was $2.7 million, 107.59% up from the prior year.
  • Income towards Parent Company for Q2 2024 was $3000.0 at Lifecore Biomedical, Inc. \De\, down from $847000.0 in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $1.8 million in Q3 2023 and troughed at -$51.6 million in Q2 2022.
  • A 5-year average of -$9.9 million and a median of -$3.6 million in 2022 define the central range for Income towards Parent Company.
  • Biggest five-year swings in Income towards Parent Company: tumbled 3184.9% in 2020 and later soared 143.44% in 2023.
  • Year by year, Income towards Parent Company stood at -$4.0 million in 2020, then tumbled by 955.02% to -$42.6 million in 2021, then soared by 91.54% to -$3.6 million in 2022, then soared by 99.33% to -$24000.0 in 2023, then soared by 112.5% to $3000.0 in 2024.
  • Business Quant data shows Income towards Parent Company for LFCR at $3000.0 in Q2 2024, $847000.0 in Q1 2024, and -$24000.0 in Q4 2023.